Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Fat necrosis

Essential points for quick revision.

Saved on this device

Synopsis

Recognise fat necrosis after trauma, surgery or radiotherapy, correlate its evolving imaging and pathological appearances, and exclude malignancy when the clinical history does not fully explain the lesion.

  • Fat necrosis is sterile inflammation and fibrosis after adipocyte injury and can follow blunt trauma, surgery, reconstruction, biopsy, anticoagulation or radiotherapy.
  • It may present as a painless hard irregular lump, skin or nipple tethering, bruising or an incidental imaging abnormality that closely mimics carcinoma.
  • A trauma history supports the diagnosis but does not prove it; patients may not recall injury, and cancer can coexist with or be mistakenly attributed to trauma.

Investigation priorities

01
Diagnostic mammographyFirst step

Identify fat density, oil cyst, dystrophic calcification, distortion or a spiculated mass.

Management branches

Postoperative lump pathwayCorrelate a mass with the surgical bed

Eight months after therapeutic mammoplasty, a patient notices a hard area beneath the lateral scar and fears recurrence.

  1. Map the mass and obtain the operation and pathology records, including resection cavity, reconstruction pattern and prior margin status.
  2. Perform diagnostic mammography and targeted ultrasound rather than judging the lesion from scar proximity or postoperative timing alone.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 8 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom